Pharming Group Exceeds Annual Targets with Revenue of $376 Million
The Dutch laboratory Pharming Group has released its unaudited preliminary results for the fiscal year 2025, reporting a revenue of approximately $376 million, according to the group's statement. This performance surpasses the revised range of $365 to $375 million announced in November 2025.
Strong Revenue Growth and Operational Performance
The total revenue for the group in 2025 stands at approximately $376 million, marking an increase of about 27% compared to 2024, the company states. This performance is attributed to the continuous growth of RUCONEST and the increasing demand for Joenja, primarily fueled by patient adoption in the United States and supported by ongoing geographic expansion. The operational expenses for the full year 2025 are expected to fall within the previously communicated range of $304 to $308 million, the group emphasizes. The complete financial results for the fourth quarter and full year 2025 will be published on March 12, 2026.
Upcoming Virtual Investor Day
Pharming Group will host a virtual investor day on February 3, 2026, at 10 AM Eastern Time, which is 4 PM Central European Time, the company announces. The agenda will include a comprehensive update on the developing portfolio, including leniolisib in Phase II clinical trials for primary immunodeficiencies with immune dysregulation, including common variable immunodeficiency with immune dysregulation, as well as KL1333 in a pivotal clinical study named FALCON for mitochondrial diseases linked to mitochondrial DNA. The group will also present its financial forecasts for 2026, highlighting anticipated revenue drivers and expectations regarding operational expenses. The program will feature presentations from leading clinical experts discussing the evolving understanding of immune dysregulation in primary immunodeficiencies and the unmet needs in mitochondrial diseases linked to mitochondrial DNA.
CEO's Statement on 2025 Performance
Fabrice Chouraqui, CEO of Pharming, stated in the announcement that the company had a strong year in 2025, driven by robust demand for its commercial assets and renewed financial discipline. According to him, RUCONEST continued to grow in an increasingly competitive environment, while the adoption of Joenja accelerated with the rise in demand from American patients and international expansion. Entering the year 2026, the group remains focused on advancing its clinical programs for other primary immunodeficiencies with immune dysregulation and primary mitochondrial diseases, while supporting the continued growth of its commercial portfolio, he added. Additional registration information for the investor day will be made available on the group's website in the coming weeks.
